FDA labeling now permits axi-cel use in R/R PCNSL, making it the first CAR T for R/R LBCL with CNS lymphoma limitations removed. Phase 1 Dana-Farber study (N=18; PCNSL n=13) prioritized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results